Oncologist最新文献_第5页

Effect of HLA restriction on racial and ethnic disparities in access to immune therapies for advanced synovial sarcoma. HLA限制对晚期滑膜肉瘤获得免疫治疗的种族差异的影响

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-24 DOI: 10.1093/oncolo/oyaf193

Vinayak Venkataraman, Hannah R Abrams, David S Shulman, Elizabeth T Loggers, Seth M Pollack, Kelly G Paulson, Michael J Wagner

{"title":"Effect of HLA restriction on racial and ethnic disparities in access to immune therapies for advanced synovial sarcoma.","authors":"Vinayak Venkataraman, Hannah R Abrams, David S Shulman, Elizabeth T Loggers, Seth M Pollack, Kelly G Paulson, Michael J Wagner","doi":"10.1093/oncolo/oyaf193","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf193","url":null,"abstract":"Purpose: Synovial sarcoma (SS) is aggressive with poor outcomes. Cellular therapies are now FDA approved for advanced disease, but are restricted to certain HLA-A*02 alleles. We estimate eligibility to cellular therapies by race and ethnicity.Materials and methods: Demographic and clinical features of SS cases from 2001 to 2020 were obtained from the United States Cancer Statistics (USCS; NPCR-SEER). Survival analyses were performed overall and by races/ethnicity. The proportion eligible for cellular therapy was estimated by races/ethnicity using previously published data on HLA-A*02 status and MAGE-A4 positivity.Results: From 2001 to 2020, 10,605 patients (48% female, 64% Non-Hispanic White, 17% Hispanic) with SS were identified. The incidence rate was 1.5-1.8/million/person-years and was stable over time, corresponding to an average 530 new cases annually. The most common primary site was the extremity (n = 5,877; 58%), and most patients presented with localized disease (n = 5,753; 54%). The 5-year cause-specific survival was 60% across all races/ethnicities and 79% for localized, 57% for regional, 12% for distant disease. Differences by race and ethnicity were found in the proportions of patients expected to be eligible for HLA-restricted cellular therapies targeting MAGE-A4. People of European/European descent had the highest estimated proportion (25-39%), and people of Asian/Pacific Islander descent had the lowest (11-17%).Conclusion: Engineered T-cells targeting MAGE-A4 have shown encouraging safety and efficacy in advanced SS; however, eligibility restrictions will lead to racial and ethnic disparities. HLA-independent solutions must be developed to counter disparities and ensure all patients have access.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-Center Phase II Study of Nab-Paclitaxel Plus Camrelizumab Versus Nab-Paclitaxel Alone as Second-Line Treatment for Advanced Gastric Cancer. nab -紫杉醇联合Camrelizumab与nab -紫杉醇单独作为晚期胃癌二线治疗的多中心II期研究

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-24 DOI: 10.1093/oncolo/oyaf189

Li Sun, Zhimin Gong, Lei Wang, Li Kuang, Qiao Huang, Bo Pei, Xianglin Yuan, Hong Qiu

{"title":"Multi-Center Phase II Study of Nab-Paclitaxel Plus Camrelizumab Versus Nab-Paclitaxel Alone as Second-Line Treatment for Advanced Gastric Cancer.","authors":"Li Sun, Zhimin Gong, Lei Wang, Li Kuang, Qiao Huang, Bo Pei, Xianglin Yuan, Hong Qiu","doi":"10.1093/oncolo/oyaf189","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf189","url":null,"abstract":"Background: Nab-paclitaxel is a standard second-line treatment for advanced gastric cancer, but the role of PD-1 inhibitors remains uncertain. This multicenter, randomized phase II trial evaluated the efficacy of nab-paclitaxel plus camrelizumab (Cam-NP) versus nab-paclitaxel alone (NP) in patients with advanced gastric adenocarcinoma resistant to prior treatment.Methods: Patients were randomized to receive either Cam-NP or NP until disease progression, intolerable toxicity, or consent withdrawal. The primary endpoint was the overall response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and safety.Results: 61 patients were randomized, with 58 receiving treatments. At a median follow-up of 34.5 months, the Cam-NP group achieved a significantly higher ORR (33.3% vs. 10.7%; p = 0.039) and longer median PFS (5.62 vs. 4.21 months; p = 0.006). Median response duration also favored Cam-NP (4.64 vs. 2.96 months; p = 0.058). While the Cam-NP group showed a longer OS (9.8 vs. 7.2 months; p = 0.087), this was not statistically significant. The most common grade 3-4 adverse event was hematological toxicity.Conclusions: Cam-NP significantly improved ORR and PFS compared to NP as a second-line treatment for advanced gastric adenocarcinoma. Larger studies and biomarker exploration are needed to validate these findings.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indirect comparison of TPF and GP induction chemotherapy regimens in nasopharyngeal carcinoma: a data-driven reassessment before the transition to induction chemoimmunotherapy. 鼻咽癌TPF和GP诱导化疗方案的间接比较：在过渡到诱导化疗免疫治疗之前的数据驱动的重新评估。

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-24 DOI: 10.1093/oncolo/oyaf175

Stefano Cavalieri, Arianna Ottini, Benedetta Lombardi Stocchetti, Lisa Licitra

引用次数: 0

Comparative Analysis of Patients' Characteristics, Treatment, and Survival Outcomes in CLL from China and the US. 中美两国CLL患者特征、治疗和生存结果的比较分析

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-23 DOI: 10.1093/oncolo/oyaf181

Yuting Yan, Yin Liu, Tonglu Qiu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Wenjie Xiong, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J Kipps, Robert Peter Gale, Jianyong Li, Jifang Zhou, Shuhua Yi

{"title":"Comparative Analysis of Patients' Characteristics, Treatment, and Survival Outcomes in CLL from China and the US.","authors":"Yuting Yan, Yin Liu, Tonglu Qiu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Wenjie Xiong, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J Kipps, Robert Peter Gale, Jianyong Li, Jifang Zhou, Shuhua Yi","doi":"10.1093/oncolo/oyaf181","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf181","url":null,"abstract":"Background: Chronic lymphocytic leukaemia (CLL) is considerably more common in Americans compared with Asians. The bases for these differences and implications for therapy outcomes are controversial and mostly unknown.Methods: We compared baseline co-variates, therapies and outcomes from two databases, Flatiron Health database in the United States (N=15,786) and Tianjin CAMS database from China (N=2,996).Results: Chinese subjects had younger age at diagnosis, more advanced Rai stage and an increased prevalence of lymphadenoma, thrombocytopenia and increased β2-microglobulin. Americans had higher rates of unmutated IGHV, TP53 deletion and cytogenetic abnormalities. These differences persisted after adjusting for age, Rai stage and IGHV mutation state. There were also substantial differences in therapy patterns between the cohorts. Median survival in Chinese was 9.7 versus 7.5 years in Americans (P<0.001). In sub-group analyses Chinese CLL had better 5-year survivals with chemotherapy (69% [95% CI, 66, 72%] versus 49% [47, 52%]; P<0.001), immune therapies (67% [63, 72%] versus 65% [64, 66%]; P=0.041) and targeted therapies (85% [81, 88%] versus 65% [64, 67%]; P<0.001). These advantages were pronounced among older patients and those with early stage, mutated IGHV and without TP53 deletion.Conclusion: This cross-sectional study identifies significant clinical and treatment outcome disparities in CLL between Eastern and Western populations, attributed to distinct genetic and molecular profiles.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thermal ablation versus surgical resection for US-detected T2N0M0 papillary thyroid carcinoma. 超声检测T2N0M0甲状腺乳头状癌的热消融与手术切除。

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-23 DOI: 10.1093/oncolo/oyaf170

Yu-Tong Liu, Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Na Yu, Yan Li, Li-Li Peng, Ming-An Yu

{"title":"Thermal ablation versus surgical resection for US-detected T2N0M0 papillary thyroid carcinoma.","authors":"Yu-Tong Liu, Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Na Yu, Yan Li, Li-Li Peng, Ming-An Yu","doi":"10.1093/oncolo/oyaf170","DOIUrl":"10.1093/oncolo/oyaf170","url":null,"abstract":"Background: Thermal ablation (TA) has demonstrated promising efficacy and safety in treating papillary thyroid carcinoma (PTC). However, comparative analyses between TA and surgical resection (SR) for treating T2N0M0 PTC remain scarce.Purpose: To compare the efficacy and safety of TA and SR in treating preoperatively US-detected T2N0M0 PTC.Materials and methods: In this retrospective study, 252 patients with preoperative US-detected T2N0M0 PTC treated by TA or SR between July 2016 and May 2024 were included. Comparative study based on propensity score matching (PSM) between the TA and SR groups was conducted.Results: After PSM, 63 patients (median age: 40 years [IQR 34-53], 49 females) in the TA group and 126 patients (median age: 41 years [IQR 32-52.5], 102 females) in the SR group were followed for a median of 35 months (IQR 18-62) and 46 months (IQR 29-60), respectively (P = 0.093). There was no evidence of differences in disease progression between the TA and SR groups (11.1% vs. 7.9%; P = 0.59) or progression-free survival rates between the TA and SR groups (86.4% vs. 89.6%, P = 0.37). Compared with SR, TA resulted in less blood loss, a shorter incision length, and shorter procedure and hospitalization times (all, P < 0.001). Although there was a relatively higher incidence of hoarseness in the TA group, no significant difference was observed between the TA and SR groups (12.7% vs. 8.7%, P = 0.444) or between the TA and lobectomy (i.e. hemithyroidectomy and subtotal thyroidectomy) groups (12.7% vs. 5.9%, P = 0.340).Conclusions: There were no significant differences in disease progression and hoarseness between TA and SR for US-detected T2N0M0 PTC. TA is an effective and safe treatment option for US-detected T2N0M0 PTC.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation of TROP-2 expression with clinico-pathological features and outcomes in HR+/HER2- Breast Cancer receiving neoadjuvant chemotherapy. HR+/HER2-乳腺癌患者接受新辅助化疗后TROP-2表达与临床病理特征及预后的相关性

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-20 DOI: 10.1093/oncolo/oyaf184

Hagar Elghazawy, Mahmoud Elghazawy, Hamdy A Azim, Mariam B Abouelkhair, Sara Hossam, Shazneil Briones, Paul A Townsend, Olivier N F Cexus, Laila M Farid

{"title":"Correlation of TROP-2 expression with clinico-pathological features and outcomes in HR+/HER2- Breast Cancer receiving neoadjuvant chemotherapy.","authors":"Hagar Elghazawy, Mahmoud Elghazawy, Hamdy A Azim, Mariam B Abouelkhair, Sara Hossam, Shazneil Briones, Paul A Townsend, Olivier N F Cexus, Laila M Farid","doi":"10.1093/oncolo/oyaf184","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf184","url":null,"abstract":"Background: Limited data exists about the associations between TROP2 protein, clinico-pathological characteristics, and outcomes in patients with early HR+/HER2- BC.Patients and methods: TROP2 membranous expression was assessed on tumour biopsy by immunohistochemistry (IHC) in 70 consecutive patients with HR+/HER2- BC who are eligible to neoadjuvant chemotherapy (NAC). TROP2 expression was correlated to initial clinico-pathological parameters and pathological response post- NAC. Furthermore, Transcriptomics analysis of TACSTD2 using SCAN-B and GSE81538 datasets was performed and correlated with clinico-pathological parameters and survival.Results: All patients showed TROP2 expression, with intermediate and high expression in 68.57% and 31.43%, respectively. High TROP2 expression showed significant correlation with high Ki-67 pre-NAC (p=0.017), while no significant correlation with pCR or RCB. High TACSTD2 expression was associated with significantly lower histological grade (p<0.0001), earlier tumour stage (p<0.0001), smaller tumour size (<20 mm, p˂0.0001), lower Ki-67 (p<0.0001), and longer overall-survival (HR= 0.76; p=0.0008), recurrence-free survival (RFS) (HR=0.64; p=0.0001) and distant-RFS (HR=0.64; p=0.0011).Conclusion: In this study, TROP2 expression by IHC was observed in all HR+/HER2- BC cases, and was not significantly correlated with pCR to NAC. In contrast, TACSTD2 expression, which was significantly positively correlated with survival in the same population, suggesting a favorable prognostic value at the transcript level. This finding warrants further investigation in future studies, particularly focusing on TACSTD2 expression at the mRNA rather than the protein level.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Safety Analysis of Pooled Data for Tislelizumab as Monotherapy or in Combination With Chemotherapy in Patients With Advanced Cancers. Tislelizumab单药或联合化疗治疗晚期癌症患者的长期安全性分析

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-20 DOI: 10.1093/oncolo/oyaf177

Caicun Zhou, Rose Huang, Yuan Yuan, Patrick Schnell, John Wu, Alysha Kadva, Jola Mehmeti, Jaffer Ajani

{"title":"Long-Term Safety Analysis of Pooled Data for Tislelizumab as Monotherapy or in Combination With Chemotherapy in Patients With Advanced Cancers.","authors":"Caicun Zhou, Rose Huang, Yuan Yuan, Patrick Schnell, John Wu, Alysha Kadva, Jola Mehmeti, Jaffer Ajani","doi":"10.1093/oncolo/oyaf177","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf177","url":null,"abstract":"Background: Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, has demonstrated efficacy and safety in solid tumors. This analysis evaluates its long-term safety.Patients and Methods: A retrospective analysis was performed on data from eight randomized phase III clinical trials involving patients with advanced gastrointestinal (GI) or lung cancers who received tislelizumab. Endpoints included immune-mediated adverse events (imAEs) by tumor type, race, and treatment duration, including early (within 1 year) and delayed (>1 year) imAEs.Results: In all, 2636 patients (1415 with GI cancer, 1221 with lung cancer) were included in the analysis, with a median follow-up of 15.4 months. Most imAEs were low grade. In GI cancers, 32.5% of patients experienced any-grade imAEs (7.3% grade ≥3). In lung cancers, 39.6% reported any-grade imAEs (8.2% grade ≥3). The most frequently reported imAEs were skin toxicity, hypothyroidism, pneumonitis, and hyperthyroidism. The incidence of imAEs was slightly higher in Asian patients compared with non-Asian patients (34.3% vs 26.9% in GI cancer and 35.5% vs 29.7% in lung cancer, respectively), but the incidence of grade ≥3 imAEs remained similar (7.5% vs 6.9% in GI cancer and 6.1% vs 7.2% in lung cancer, respectively). Most imAEs occurred within 6 months of treatment initiation. Delayed imAEs were infrequent and predominantly occurred while patients were still receiving tislelizumab therapy.Conclusion: Tislelizumab's safety profile, as monotherapy or combined with chemotherapy, remains consistent with previous reports across tumor types. Delayed imAEs were relatively infrequent, with no new signals identified in this long-term safety analysis.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient Reported Tolerance of 90 Days of Pre-Operative Endocrine Therapy: Results from the POWER Trial. 患者报告术前90天内分泌治疗的耐受性：POWER试验的结果。

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-16 DOI: 10.1093/oncolo/oyaf172

Trish Millard, Lena Turkheimer, Jenna Schlefman, Gina Petroni, David Brighton, Shayna Showalter

{"title":"Patient Reported Tolerance of 90 Days of Pre-Operative Endocrine Therapy: Results from the POWER Trial.","authors":"Trish Millard, Lena Turkheimer, Jenna Schlefman, Gina Petroni, David Brighton, Shayna Showalter","doi":"10.1093/oncolo/oyaf172","DOIUrl":"https://doi.org/10.1093/oncolo/oyaf172","url":null,"abstract":"Background: Prospective randomized data supports radiation omission in women ≥ 65 years who take adjuvant endocrine therapy (AET) following breast-conserving surgery. Many patients who omit radiation stop AET early due to side effects. In the POWER trial, a prospective single-arm study, patients took 90 days of pre-operative endocrine therapy (pre-ET) to assess tolerance before making adjuvant treatment decisions. We hypothesized that patient-reported outcomes (PROs) during pre-ET would be heterogeneous and that 90 days was sufficient time for symptoms to develop.Patients and methods: PRO data from POWER trial participants was obtained before, during, and after pre-ET, including health-related quality of life (HRQoL), depression, and ET symptoms using the EORTC-QLQ, CESD-R, and BCPT-SCL tools. PRO assessments were further analyzed after stratifying patients by high or low perceived sensitivity to medicine (PSM).Results: Pre-ET PROs were assessed for 75 participants. The majority (73.3%) reported symptoms during pre-ET. Only 10.7% had symptoms severe enough to stop pre-ET before 90 days. Vasomotor (42.7%) and musculoskeletal (41.3%) symptoms were the most common. HRQoL was preserved for 66.6% participants. Patients with high PSM had more ET side effects.Conclusion: Patients developed similar side effects during pre-ET as those typically seen with AET. PROs and the impact of pre-ET on HRQoL were patient-dependent. A 90-day course of pre-ET is sufficient for patients to develop symptoms reflective of long-term AET. Future analyses will assess the association of pre-ET PROs with AET initiation and adherence.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma. 基线总病灶糖酵解识别早期自然杀伤/ t细胞淋巴瘤免疫抑制特征的高危患者。

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-04 DOI: 10.1093/oncolo/oyaf164

Xiao Gao, Jie Xiong, Xin-Yun Huang, Hao-Xu Yang, Hui-Juan Zhong, Shu Cheng, Xu-Feng Jiang, Wei-Li Zhao

{"title":"Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma.","authors":"Xiao Gao, Jie Xiong, Xin-Yun Huang, Hao-Xu Yang, Hui-Juan Zhong, Shu Cheng, Xu-Feng Jiang, Wei-Li Zhao","doi":"10.1093/oncolo/oyaf164","DOIUrl":"10.1093/oncolo/oyaf164","url":null,"abstract":"Background: The post-treatment Deauville scale (DS) and circulating Epstein-Barr virus (EBV)-DNA were used for prediction of long-term remission in natural killer/T-cell lymphoma (NKTCL). However, the baseline biomarkers still remain lacking for clinical application. Here, we hypothesized that 18F-FDG PET/CT, as a measure of total tumor burden, would be a baseline biomarker to identify high-risk NKTCL patients.Methods: We analyzed PET/CT data in early-stage NKTCL patients (n = 192) receiving pegaspargase-based regimens from 2 independent clinical trials. The prognostic values of radiomic markers including total lesion glycolysis (TLG), standardized uptake value, and metabolic tumor volume were evaluated in the training (n = 127) and validation cohorts (n = 65) with a median follow-up of 37 months.Results: Total lesion glycolysis was a prognosticator of progression-free survival (PFS) and overall survival (OS), with 86.11% and 91.30% sensitivity and 55.77% and 53.25% specificity, respectively, which outperformed the risk model based on posttreatment DS and circulating EBV-DNA (sensitivity 53.85% and specificity 54.24% for PFS, sensitivity 43.75% and specificity 52.34% for OS). Five-year PFS and OS were 92.19% and 96.82% in the low TLG group (<75 g), versus 69.46% and 77.24% in the high TLG group (≥75 g). ScRNA-seq (n = 10) and bulk RNA-seq (n = 65) data from patients in the trials both revealed that inflammatory dendritic cells, as immunosuppressive signature, were significantly infiltrated in patients with high TLG compared with patients with low TLG.Conclusions: Baseline TLG reflected an immunosuppressive microenvironment and was an effective radiomic marker for long-term remission in patients with early-stage NKTCL.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of financial hardship and survival in working-age patients following cancer diagnosis in Taiwan. 台湾工作年龄癌症患者经济困难与生存之关系。

IF 4.8 2区医学

Oncologist Pub Date : 2025-06-04 DOI: 10.1093/oncolo/oyaf140

Yi-Yun Claire Ciou, Li-Nien Chien

{"title":"Association of financial hardship and survival in working-age patients following cancer diagnosis in Taiwan.","authors":"Yi-Yun Claire Ciou, Li-Nien Chien","doi":"10.1093/oncolo/oyaf140","DOIUrl":"10.1093/oncolo/oyaf140","url":null,"abstract":"Background: Extreme income or asset loss as severe form of financial hardship (FH) has been linked to worse survival outcomes in cancer patients. This study aimed to assess the incidence, risk factors, and impact of severe financial hardship (SFH) on survival among working-age cancer patients in Taiwan's universal healthcare system, using an objective measure for SFH.Methods: This study analyzed linked national longitudinal data for patients aged 20-63 years diagnosed with cancer between 2007 and 2018. Severe financial hardship was defined as household net income falling below the poverty threshold post-diagnosis. Propensity score matching (1:4) was used to balance baseline characteristics between SFH and non-SFH groups. Cox proportional hazard models were used to estimate the hazard ratio (HR) of outcomes.Results: Among 400 229 working-age cancer patients, the incidence of SFH was 4.7 per 1000 person-years (95% confidence interval [CI], 4.6-4.9) over a mean follow-up of 5.7 ± 4.3 years. Severe financial hardship was associated with younger age, male sex, advanced stage, and intensive treatments. Patients with SFH within 1 year of diagnosis had significantly lower survival, with an adjusted HR of 1.64 (95% CI, 1.56-1.72) for all-cause mortality compared to those without SFH. Notably, early stage patients with SFH faced a higher relative mortality risk than advanced-stage patients.Conclusions: Severe financial hardship substantially increases mortality among cancer patients in Taiwan, highlighting gaps in financial protection. Addressing SFH through implementing targeted policies and enhancing support mechanisms is essential to improve survival outcomes and reduce disparities in cancer care.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12200238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0